NCT03497689已完成4 期
EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension
United Therapeutics11 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2019年1月31日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
- 试验地点
- 11
- 主要终点
- Number of Subjects Achieving Oral Treprostinil Dose
研究概览
简要总结
This was a multicenter, open-label study to evaluate the dose of Orenitram® (treprostinil) Extended Release Tablets achieved at 16 weeks after a short-term course of Remodulin® (treprostinil) Injection in subjects with pulmonary arterial hypertension (PAH).
详细描述
Subjects were initiated on subcutaneous (SC) or intravenous (IV) treprostinil and titrated to a dose that improved the symptoms of PAH while minimizing excessive pharmacologic effects. After achieving a minimum SC/IV treprostinil dose of 20 ng/kg/min, subjects began a transition to oral treprostinil at the Transition Visit, which occurred at the Week 2, 4, or 8 study visit. After the Transition Visit, oral treprostinil titration continued through Week 16 to reach the maximum tolerated dose (MTD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who voluntary gave written informed consent to participate in study.
- •Males and female subjects aged 18 to 75 years at Screening (date the subject provided written informed consent to participate in study).
- •Subjects with a diagnosis of World Health Organization (WHO) Group 1 pulmonary hypertension (PH): symptomatic idiopathic or heritable PAH; or PAH associated with connective tissue disease, human immunodeficiency virus (HIV) infection, repaired congenital systemic-to-pulmonary shunt (at least 1 year since repair with respect to the date of providing informed consent), or appetite suppressant/toxin use.
- •Subjects with WHO functional class (FC) II or III symptoms at Baseline.
- •Subjects with 6MWD >250 m at Baseline.
- •Subjects who were either not receiving PAH-targeted therapy or were currently being treated with 1 or 2 oral FDA-approved PAH therapies consisting of an endothelin receptor antagonist (ERA) and/or either a phosphodiesterase type-5 inhibitor (PDE5-I) or a soluble guanylate cyclase (sGC) stimulator for ≥45 days, and on a stable dose for ≥30 days prior to the Baseline Visit.
- •Subjects on stable doses of other medical therapies for at least 10 days prior to the Baseline Visit, with no dose adjustments, additions, or discontinuations, with the exception of discontinuation or dose changes of anticoagulants and/or diuretics. Subjects could not have recent changes to non-pharmacologic interventions, such as exercise, diet plans, pulmonary rehabilitation, or sleep apnea treatment, for at least 10 days prior to Baseline Visit.
- •Subjects with historical right heart catheterization (RHC) results consistent with WHO Group 1 PH, as demonstrated by pulmonary artery pressure mean of ≥25 mmHg, a pulmonary artery wedge pressure (PAWP) or left ventricular (LV) end-diastolic pressure ≤15 mmHg (if a PAWP measurement was not available) and a pulmonary vascular resistance (PVR) >3 Wood units, in the absence of unrepaired congenital heart disease (other than patent foramen ovale).
- •Subject underwent an RHC within 180 days of Baseline and had a cardiac index ≥2.0 L/min/m² with no changes in their PAH medication regimen (ie, both dosing and drug) since the RHC.
- •Subjects with most recent historical echocardiogram (ECHO) demonstrating clinically normal left systolic and diastolic ventricular function and absence of any clinically significant left-sided heart disease. Subjects with clinically insignificant LV diastolic dysfunction due to the effects of right ventricular (RV) overload (RV hypertrophy and/or RV dilation) were eligible.
- •Subjects who agreed to follow the specified precautions to avoid pregnancy as follows:
- •For female subjects of childbearing potential, a negative urine pregnancy test was required at Screening and Baseline prior to initiating study drug. Female subjects of childbearing potential must have followed 1 of the following approaches: i. practice actual abstinence from intercourse, ii. had a partner with a vasectomy, iii. had an intrauterine device, or iv. must have used 2 different forms of highly effective contraception for the duration of the study, and for at least 48 hours after discontinuing study drug. Medically acceptable forms of effective contraception included approved hormonal contraceptives (such as birth control pills) or barrier methods (such as a condom or diaphragm).
- •Male subjects with a partner of childbearing potential must have used a condom during intercourse for the duration of the study, and for 48 hours after discontinuing study drug.
- •HIV-positive subjects must have had a CD4 lymphocyte count of at least 200 cells/mm^3 within 30 days of Screening and been receiving current standard-of-care anti-retroviral or other effective medication for the treatment of HIV, with no changes for at least 8 weeks prior to enrollment.
- •Subjects who, in the opinion of the Investigator, were capable of communicating effectively with study personnel and were considered reliable, willing, and likely to be cooperative with protocol requirements and attend all required study visits.
- •Subjects who had the capability to answer surveys and questionnaires written in English.
排除标准
- •Female subjects who were pregnant, lactating, or planning to become pregnant during the study.
- •Subjects with a current diagnosis of uncontrolled sleep apnea, as defined by their physician.
- •Subjects with renal insufficiency, as defined by requiring dialysis or an estimated creatinine clearance of <30 mL/min, as calculated by the Cockcroft-Gault equation.
- •Subjects with liver dysfunction defined as elevated liver function tests (alanine aminotransferase or aspartate aminotransferase) ≥3 times the upper limit of normal at Screening, or subjects with Child-Pugh Class B or C hepatic disease.
- •Subjects with anemia, as defined by Screening hemoglobin <9 g/dL.
- •Subjects with an active infection or condition that interfered with interpretation of study assessments.
- •Subjects with a history of ischemic heart disease (defined as subjects who required anti-anginal therapy within 6 months of Screening or who had experienced a documented myocardial infarction within 6 months of Screening) or a history of left-sided myocardial dysfunction, as evidenced by a PAWP >15 mmHg or LV ejection fraction <50%.
- •Subjects with uncontrolled systemic hypertension, as evidenced by systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg at Baseline.
- •Subjects with severe hypotension, as evidenced by systolic blood pressure <90 mmHg or diastolic blood pressure <50 mmHg at Baseline.
- •If a lung assessment was completed as per standard of care, any subject with 1 or more of the following signs of documented relevant lung disease within 180 days of Baseline: total lung capacity <60% of predicted or forced expiratory volume in 1 second <55% of predicted normal.
- •Subjects with chronic musculoskeletal disorder or any other disease that limited ambulation, or who were connected to a machine that was not portable.
- •Subjects with a history of alcohol abuse or illicit drug abuse within 12 months of Baseline which, in the Investigator's opinion, made the subject inappropriate for enrollment in a clinical study.
- •Subjects with any other concomitant disease with life expectancy of <12 months from Baseline.
- •Subjects with an unstable psychiatric condition or those not capable of understanding the objectives, nature, or consequences of the study, or who have any condition which, in the Investigator's opinion, constituted an unacceptable risk to the subject's safety.
- •Subjects who were currently receiving an investigational drug, had an investigational device in place, or who had participated in an investigational drug or device study within 180 days prior to Baseline. Participation in an observational study within 180 days prior to Baseline did not disqualify a subject from enrolling.
- •Subjects who had received a prostacyclin-class therapy within 28 days of Baseline.
- •Subjects who had a Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) 2.0 Risk Score of ≥10.
研究组 & 干预措施
Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
Experimental
Subjects began Remodulin at 2 ng/kg/min subcutaneously (SC) or intravenously (IV) and were optimized to their maximum tolerated dose (MTD) of Remodulin. Subjects were then transitioned to Orenitram XR tablets (oral) based upon their Remodulin dose. Subjects were optimized on Orenitram therapy to a MTD. There were no maximum Remodulin or Orenitram doses specified during the study.
干预措施: Intravenous/Subcutaneous Treprostinil; Oral Treprostinil (Drug)
结局指标
主要结局
Number of Subjects Achieving Oral Treprostinil Dose
时间窗: Assessed at Week 16
The number of subjects that achieved an oral treprostinil dose of ≥4 mg TID (or a total daily dose \[TDD\] of 12 mg) at Week 16 (or a dose of ≥0.057 mg/kg TID \[TDD of 0.171 mg/kg\] for subjects \<70 kg).
次要结局
- Change in Serum N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Levels(From Baseline to Week 16)
- Change in Echocardiogram Parameters (Left Ventricular Outflow Track Dimension)(At Baseline and Week 16)
- Change in Echocardiogram Parameters (LVOT Velocity Time Integral)(At Baseline and Week 16)
- Change in Echocardiogram Parameters (LV Diameter)(At Baseline and Week 16)
- Change in Echocardiogram Parameters (RV Diameter)(At Baseline and Week 16)
- Change in Echocardiogram Parameters (RV Free Wall Strain)(At Baseline and Week 16)
- Change in Echocardiogram Parameters (RV Myocardial Performance Index)(At Baseline and Week 16)
- Change in PAH Symptom Score(At Baseline and Week 16)
- Change in Echocardiogram Parameters (Heart Rate)(At Baseline and Week 16)
- Number of Subjects With Changes in WHO FC(From Baseline to Week 16)
- Improvement From Baseline in Clinical Risk Category(At Baseline and Week 16)
- Change in 6-minute Walk Distance (6MWD)(From Baseline to Week 16)
- Change in Borg Dyspnea Score(From Baseline to Week 16)
- Change in Echocardiogram Parameters (Change in Cardiac Output)(At Baseline and Week 16)
- Change in Echocardiogram Parameters (LV Eccentricity Index [Systole])(At Baseline and Week 16)
- Change in Echocardiogram Parameters (Pulmonary Valve Acceleration Time)(At Baseline and Week 16)
- Change in Echocardiogram Parameters (RV/LV Ratio)(At Baseline and Week 16)
- Change in Echocardiogram Parameters (Right Atrial Area)(At Baseline and Week 16)
- Change in Echocardiogram Parameters (Tricuspid Annular Plane Systolic Excursion)(At Baseline and Week 16)
- Change in Echocardiogram Parameters (LV Eccentricity Index [Diastole])(At Baseline and Week 16)
- Change in Patient-reported Outcomes (Health-related Quality of Life)(At Baseline and Week 16)
- Change in Treatment Satisfaction(At Baseline and Week 16)
- Achievement of Low Risk Category in Clinical Parameters(At Week 16)
- Overall Achievement(At Week 16)
- Transition and Maintenance of Orenitram Therapy(At Week 16)
研究者
研究点 (11)
Loading locations...
相似试验
终止
3 期
Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEFPulmonary Hypertension Associated With HFpEFNCT03043651United Therapeutics48
终止
1 期
Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)ALSFTDFrontotemporal DementiaAmyotrophic Lateral SclerosisNCT05683860Wave Life Sciences USA, Inc.8
已完成
4 期
Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVORetinal Vein OcclusionNCT01580020Novartis Pharmaceuticals175
已完成
2 期
A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic DermatitisModerate to Severe Atopic DermatitisNCT06012812Shanghai Hengrui Pharmaceutical Co., Ltd.79
撤回
不适用
Oxulumis®, Suprachoroidal Drug Administration of Triesence® in Diabetic Macular EdemaDiabetic Macular EdemaNCT05172401Oxular Limited